РЕПЕРФУЗИЯ У БОЛЬНЫХ ОСТРЫМ ИНФАРКТОМ МИОКАРДА

1. Руда М.Я. Что нужно знать практическому врачу о тромболитической терапии при инфаркте миокарда?//Сердце: журнал для практикующих врачей. 2002. Т. 1, № 1. C. 9-12.

2. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major mortality results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322.

3. Максименко А.В., Тищенко Е.Г. Комбинированный тромболизис -новое направление исследование активаторов плазминогена третьего поколения//Вопросы биологической медицины и фармакологической химии. 2000. № 1. С. 1-10.

4. Clinical Cardiology. Bolus Fibrinolytic Therapy in Acute Myocardial infartion. JAMA 2001; 286(4).

5. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 2002. С. 735.

6. А.А. Куприна, А.А. Упницкий, Ю.Б. Белоусов. Алтеплаза: клиническая фармакология, перспективы применения при остром инфаркте миокарда, фармакоэкономические аспекты//Фарматека. 2004. № 19-20(96). С. 17-20.

7. Sabatine M.S., Cannon С.Р., Gibson C.M., et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infartion with ST-Segment Elevation. N. Engl. J. Med. 2005 Mar; 10: 352.

8. Mehilli J., et al. Gender and Myocardial Salvage After Reperfusion Treatment in Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2005; 45: 828-31.

9. Gerschlic A.H., Stephens-Lloyd A.S., Hughes S., et al. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infartion. N. Engl. J. Med. 2005; 353: 2758-68.

10. De Wood M.A., Spores J., Notske R.N., et al. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980; 303: 897.

11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.

12. The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N. Engl. J. Med. 1993; 329: 1615-22.

13. Чернецов В.А., Господаренко А.Л. Предикторы возникновения рецидивирующих расстройств кровообращения у больных крупноочаговым инфарктом миокарда после тромболитической терапии//Российский кардиологический журнал. 1999. № 6. С. 11-14.

14. Andrews J. ST-segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation 2000; 101: 2138, AHA.

15. Braunwald E. Heart disease. London. WB Saunders Company; 1997. pр. 1184-1289.

16. Le May M.R., Wells G.A., Labinaz M., et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study). J. Am. Coll. Cardiol. 2005; 46(3): 417-24.

17. Schomig A., Mehili J., Antonicci D., et al. Mechanical Reperfusion in Patients Wth Acute Myocardial Infartion Presenting More Than 12 Hours From Symptom Onset. A Randomized Controlled Trial. JAMA 2005; 293: 2865-2872.

18. Fernandes-Avilas F., Alonso J.J., Castro-Beiras A., et al. Routine invasive strategy within 24 hours of thrombolysis versus ischami-aquided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-53.

19. Yellon D.M., Baxter G.F. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality. Heart 2000; 83: 381-387.

20. Kloner R.A. Does reperfusion injury exist in human? J. Am. Coll. Cardiol. 1993; 21: 537.

21. Jennings R.B., Schaper J., Hill M.L., et al. Effect of reperfusion late in the phase of reversible ischaemic injury: Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ Res 1985; 56: 262

22. Braunwald E., Kloner R.A. Myocardial reperfusion: A double-edged sword? J. Clin. Invest. 1985; 76: 1715.

23. Ito H., Iwakura K., Oh H., et al. Temporary changes in myocardial perfusion in patients with reperfused anterior myocardial infarction. Circulation 1995; 91: 656-62.

24. Ito H., Tomooka T., Sakai N., et al. Lack of myocardial perfusion immediately after successful thtombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-705.

25. Solomon S.D., Ridker P.M., Antman E.M. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction: A meta-analysis. Circulation 1993; 88: 2575.

26. Vera Z., Pride H.P., Zipes D.P. Reperfusion arrhythmias: Role of early afterdepolarisations studied by monophasic action potential recordings in the infarct canine heart during autonomically denervated and stimulated sites. J. Cardiovasc. Electrophysiol. 1995; 6: 532.

27. Дядык А.И., Багрий А.Э. Приколота О.А. и др. Желудочковые нарушения ритма при остром инфаркте миокарда. Часть 1. Эпидемиология, клиническая характеристика и прогностическая значимость. // Украинский кардиол. журн. 2001. № 3. C. 92-98.

28. Chiladacis J., Karapanos G., Davlouros P. Significant of R-on T-phenomenon in early ventricular tachyarrhythmia susceptibility after acute myocardial infarction in the thrombolytic era. Am. J. Cardiology. 2000. Vol. 85, N 3. P. 289-293.

29. Ferrari R., Cecconi C., Curello S., Cargnoni A., et al. Occurrence of oxidative stress during myocardial reperfusion. Mol. Cell. Biochem. 1992; 111: 61-9.

30. Ferrari R., Niccoli L., Vision O., Harris P. Myocardial metabolism during intracoronary thrombolysis. Int. J. Cardiol. 1987; 15: 293-9.

31. Jennings R.B., Hawkins H.K., Lowe J.E., Hill M.L., Klotman S., Reimer K.A. Relation between high-energy phosphate and lethal injury in myocardial ischemia in the dog. Am. J. Pathol., 1978; 92: 187-214.

32. Rao V., Ivanov J., Weisel R.D., et al. Lactate release during reperfusion predicts low cardiac output syndrome after coronary bypass surgery. Ann. Thorac. Surg. 2001; 71: 1925-1930.

33. Rao V., Merante F., Weisel R.D., et al. Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from simulated ischaemia. J. Thorac. Cardiovasc. Surg. 1998; 116: 485-494.

34. Bolli R., Jeroudi M.O., Patel B.S., et al. Direct evidence that oxygen-derived free radicals contribute to post-ischaemic myocardial dysfunction in the intact dog. Proc. Nat. Acad. Sci. USA. 1989; 86: 4695-4699.

35. Coronary endotelial dysfunction after iscemiaand reperfusion and its prevention by iscemic preconditioning/P. Pagliaro, A. Chiribiri, D. Mancardi e.a. Ital. Heart. J. 2003. Vol. 4, N 6. P. 383-394.

36. Steg P.G., Grollier G., Gallay P., et al. A randomized double-blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Evidence for improved myocardial reperfusion from ST-segment analysis. Eur. Heart. J. 1998; 19: 365 (abstract).

37. Gao W.D., Atar D., Liu Y., et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ. Res. 1997; 80: 393-399.

38. Gao W.D., Liu Y., Mellgren R., et al. Intrinsic myofilament alterations underlying the decreased contractility of stunned myocardium: a consequence of Ca2+-dependent proteolysis? Circ. Res. 1996; 78: 455-465.

39. Przyklenk K. Parmacological treatment of the stunned myocardium: the concepts and the challenges. Coron. Artery. Dis. 2001; 12: 363-369.

40. Vallance P., Chan N. Endotelial Function and nitric oxide: clinical relevance. Heart. 2001. Vol. 85, N 3. P. 342-350.

41. Granger D.N. Ischaemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 1999; 6: 167-178.

42. Pfeffer M.A. Left ventricular remodeling after acute myocardial infarction. Ann. Rev. Med. 1995; 46: 455.

43. Klootwijk P. Noninvasive assessment of reperfusion and re-occlusion after thrombolysis in acute myocardial infarction. Am. J. Cardiol. 1993; 72: 75G-84G.

44. Амосова Е.Н. Метаболическая терапия повреждения миокарда, обусловленного ишемией, новый подход к лечению ишемической болезни сердца и сердечной недостаточности. // Украинский кард. журн. 2000. № 4. C. 85-92.

45. Б.В. Дубовик, А.А. Жданов, Д.И. Романовский. Сравнительная кардиоцитопротекторная эффективность аргинина гидрохлорида и аргинина сукцината при ишемическо-реперфузионном поражении миокарда у крыс//Бел. мед. журн. 2005. 4 (14). С. 12-16.

46. Lopaschuk G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease//Eur. Heart. J. 1999; 1 (suppl O): 032-039.

47. Lopaschuk G.D., Kozak R. Trimetazidine inhibits fatty acids oxidation in the heart//J. Mol. Cell. Cardiol. 1998; 30: A112.

48. European Heart Journal (1997) 18, suppl F, F2-F10.